Needle-free injection technology company PharmaJet revealed on Tuesday that it has been awarded a UNICEF tender to provide its WHO-prequalified Tropis intradermal (ID) delivery system for a polio vaccination campaign in Afghanistan beginning in August 2025.

This initiative is led by the National Emergency Operation Center (NEOC) Afghanistan with support from WHO, UNICEF, and other Global Polio Eradication Initiative partners.

The campaign, focused on Afghanistan's Eastern region, will administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children under five, alongside oral polio vaccine (OPV). This marks the first large-scale use of Tropis ID in Afghanistan following successful deployments in Pakistan, Nigeria, and Somalia.

Polio remains endemic in Afghanistan and Pakistan, with wild poliovirus type 1 transmission rising in Afghanistan during 2024. The site-to-site immunisation model enabled by Tropis ID is expected to increase vaccine coverage, reduce programme costs, and improve community acceptance.

The programme supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new cases in the East and South, and prevent local transmission in other parts of the country.